Takeda has laid out considerable time, effort and money on its dengue vaccine program despite Sanofi’s trouble with its earlier entrant. Now, the Japanese drugmaker is touting phase 3 data showing the vaccine was 80% effective at preventing dengue. More: Takeda's dengue shot
read moreIndia’s Aurobindo, which has yet to meet FTC terms to complete a $1 billion deal to buy a significant chunk of Sandoz U.S. generics business, also continues to struggle to meet FDA terms for its manufacturing plants. More: Aurobindo is finding
read moreGW Pharma topped expectations with $86.1 million in Epidiolex sales in the third quarter. Still, investors punished the company, sending shares down by 15% on Wednesday. They might have overlooked some key data—or the drug simply failed to hit “whisper
read moreRegeneron’s sixth-to-market PD-1 inhibitor Libtayo has been slow to catch on, but the company hopes to make headway in new markets and with combination immuno-oncology regimens. But analysts aren’t optimistic about the drug’s growth prospects, and newly released data isn’t
read moreTakeda has yet to file for approval of its vaccine candidate to treat dengue but it now has a €130 million plant and 200 jobs relying on that nod. More: Takeda opens €130M plant to produce dengue vaccine it has
read moreThe drug has been approved and marketed in Europe as Ziextenzo since 2018. More: FDA grants Sandoz approval for Ziextenzo in oncology care Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals